About Ena Respiratory
Ena Respiratory is a company based in Melbourne (Australia) founded in 2020.. Ena Respiratory has raised $52.4 million across 3 funding rounds from investors including Gates Foundation, Flu Lab and Uniseed. Ena Respiratory offers products and services including INNA-051. Ena Respiratory operates in a competitive market with competitors including aTyr Pharma, ReCode Therapeutics, InterMune, GEn1E and Pulmatrix, among others.
- Headquarter Melbourne, Australia
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$52.4 M (USD)
in 3 rounds
-
Latest Funding Round
$22.4 M (USD), Series B
Oct 22, 2025
-
Investors
Gates Foundation
& 5 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ena Respiratory
Ena Respiratory offers a comprehensive portfolio of products and services, including INNA-051. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Nasal product boosts immune defense to clear viral respiratory infections.
Funding Insights of Ena Respiratory
Ena Respiratory has successfully raised a total of $52.4M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $22.4 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $22.4M
-
First Round
First Round
(16 Jun 2021)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2025 | Amount | Series B - Ena Respiratory | Valuation |
investors |
|
| Feb, 2025 | Amount | Series B - Ena Respiratory | Valuation |
investors |
|
| Jun, 2021 | Amount | Series B - Ena Respiratory | Valuation | Minderoo Foundation , Brandon Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ena Respiratory
Ena Respiratory has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, Flu Lab and Uniseed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed-stage investments are directed toward Australian companies.
|
Founded Year | Domain | Location | |
|
Early-stage medical companies are funded by this venture capital firm.
|
Founded Year | Domain | Location | |
|
Venture capital investments are made in frontier research and technology.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ena Respiratory
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ena Respiratory
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ena Respiratory Comparisons
Competitors of Ena Respiratory
Ena Respiratory operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as aTyr Pharma, ReCode Therapeutics, InterMune, GEn1E and Pulmatrix, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Protein biologics are developed for treating rare diseases.
|
|
| domain | founded_year | HQ Location |
Precision medicines for lung-related diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies in pulmonology and orphan fibrotic diseases.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of inflammatory and rare diseases
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of respiratory diseases
|
|
| domain | founded_year | HQ Location |
Respiratory disease drugs for asthma and COPD are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ena Respiratory
Frequently Asked Questions about Ena Respiratory
When was Ena Respiratory founded?
Ena Respiratory was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Where is Ena Respiratory located?
Ena Respiratory is headquartered in Melbourne, Australia. It is registered at Melbourne, Victoria, Australia.
Is Ena Respiratory a funded company?
Ena Respiratory is a funded company, having raised a total of $52.4M across 3 funding rounds to date. The company's 1st funding round was a Series B of $25M, raised on Jun 16, 2021.
What does Ena Respiratory do?
Ena Respiratory was founded in 2020 in Melbourne, Australia, operating in the biotechnology sector. Prophylactics are developed to activate the bodys natural responses against viral respiratory infections. A lead nasal spray is advanced for weekly self-administration among at-risk populations. Clinical and preclinical studies have shown activity against multiple viruses. Funding and partnerships are utilized for development and pandemic response initiatives.
Who are the top competitors of Ena Respiratory?
Ena Respiratory's top competitors include aTyr Pharma, ReCode Therapeutics and Pulmatrix.
What products or services does Ena Respiratory offer?
Ena Respiratory offers INNA-051.
Who are Ena Respiratory's investors?
Ena Respiratory has 6 investors. Key investors include Gates Foundation, Flu Lab, Uniseed, Minderoo Foundation, and Brandon Capital.